

NRC Matters

I write with great concern about the recent article "Is the NRC ready for reform?" by Andrew Lawler (9 May, p. 900). First, let me say that I am pleased that *Science* shows such a strong interest in the National Research Council (NRC). Dissemination of our work is crucial to its effectiveness, so we are always appreciative when our work is publicized. Nevertheless, I was disappointed in the article. I spent an hour or so talking with Lawler about a range of issues concerning the NRC—from studies that have had enormous impact on policy, to issues surrounding the Federal Advisory Committee Act, to changes within the NRC structure and how I view the future.

When Lawler asked me about changes within the NRC operations, I talked at length about measures that have been taken to cut costs and to use our resources more prudently.

Additionally, tremendous changes have been brought about by our chief operating officer, Suzanne Woolsey, in her efforts to bring more efficiency to our operations—particularly to our multimillion-dollar information services side of the house, which encompasses a complex set of functions including computers, networks, a major Inter-

net initiative, and path-breaking ventures in electronic publishing.

I cannot comment on what others may have said, but I was disappointed that I was misquoted (see Corrections and Clarifications, 18 July, p. 301) and that the article did not reflect what I believe was the full range of my conversation with Lawler.

Bruce Alberts
President,

National Academy of Sciences,
2101 Constitution Avenue,
Washington, DC 20418, USA

I was pleased to read of the new NRC procedure starting with the appointment of principal investigators with opposing biases (A. Lawler, News & Comment, 20 June, p. 1786). This, in my opinion, is much closer than traditional NRC committee procedures to the way science is done. When, for example, scientist A publishes a discovery, he gives instructions for replication of his results (as he must). His competitor, scientist B, takes the effort to replicate, conscious of the rewards for that effort. B's rewards are much greater for finding that A was wrong than for simply replicating A's discovery. B is thus motivated toward critical examination of A's work. This is a mechanism that impels scientists to publish cautiously and to frankly

acknowledge uncertainty. The advantages of providing that same frankness and caution to policy-makers (even when they don't want it) are obvious.

Arthur Kantrowitz
Dartmouth College,
Hanover, NH 03755, USA
E-mail: ark@dartmouth.edu

Corrections and Clarifications

The mosquito shown in the photo accompanying the News & Comment article "Resurgent mosquitoes, dengue in Cuba" by Gary Taubes (11 July, p. 174) was misidentified as *Aedes aegypti*.

Letters to the Editor

Letters may be submitted by e-mail (at science_letters@aaas.org), fax (202-789-4669), or regular mail (*Science*, 1200 New York Avenue, NW, Washington, DC 20005, USA). Letters are not routinely acknowledged. Full addresses, signatures, and daytime phone numbers should be included. Letters should be brief (300 words or less) and may be edited for reasons of clarity or space. They may appear in print and/or on the World Wide Web. Letter writers are not consulted before publication.

Accumulating raw genetic information is just the beginning of what automated DNA sequencing can offer you. Deciphering that data and generating accurate results to specific applications—that's what counts.

Our dedicated, automated DNA analysis software can tell Alicia in seconds

Nobody can offer you more dedicated software products for sequencing applications than Pharmacia Biotech—including three new automated DNA analysis application software called AlleleLinks™, HLA SequiTyper™ and Mutation Analyser. All three let you go from evaluation to results in seconds. All three significantly reduce your analysis time by transforming large amounts of raw data into results. As they only operate with ALF[®] automated DNA sequencers, with all three you'll get the type of extremely reproducible and accurate results only single dye chemistry can deliver.

HLA SequiTyper: quickly determines subtypes of HLA Class I and Class II genes by comparing your results against a data base built on the findings of HLA typing communities.

AlleleLinks: this fully-automated genotyping software automatically scores alleles utilizing locus data bases. Supporting X-linkage and large pedigrees, it provides simultaneous analysis of multiple gels. **Mutation Analyser:** simultaneously analyzes entire genes while giving you direct access to raw data. Ideal for confirmatory sequencing—you can link your results to others' findings (i.e. clinical records)—Mutation Analyser offers convenience, fast analysis and accurate results.

Go to <http://www.biotech.pharmacia.se/seq/seq.htm#seq6> for more information on these software; look within our home page for details about ALFexpress[®]. And start getting the most from automated DNA analysis products—like quick, accurate, and reproducible genetic results.



**Pharmacia
Biotech**

Uppsala, Sweden. (And the rest of the world.)

Circle No. 30 on Readers' Service Card

